Stocktoria
NORTHWEST BIOTHERAPEUTICS INC NWBO
OTC · OOTC · stock · Pharmaceutical Preparations · website · IPO 2001-12-14
NORTHWEST BIOTHERAPEUTICS INC financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.9M | $1.7M | $1.0M | $1.3M | $2.4M | $412,000 | $336,000 | $623,000 |
| R&D expense | $28.8M | $34.9M | $27.7M | $35.5M | $20.3M | $33.6M | $14.1M | $18.2M | $33.5M | $60.1M |
| Operating income | -$59.9M | -$66.5M | -$55.5M | -$67.2M | -$52.7M | -$86.6M | -$28.0M | -$41.5M | -$54.7M | -$79.3M |
| Interest expense | — | — | $5.2M | $6.1M | $5.0M | $8.5M | $3.0M | $9.9M | $5.5M | $3.8M |
| Income tax | -$537,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$60.2M | -$83.8M | -$62.6M | -$105.0M | $179.1M | -$529.8M | -$20.8M | -$35.8M | -$73.1M | -$80.2M |
| EPS (diluted) | $-0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.06 | $-0.73 | $-0.04 | — | — | — |
| Operating cash flow | -$44.8M | -$57.0M | -$53.6M | -$52.8M | -$38.3M | -$32.1M | -$31.9M | -$34.6M | -$36.5M | -$55.7M |
| Free cash flow | -$46.3M | -$58.0M | — | — | — | — | -$32.0M | — | — | — |
| Cash & equivalents | $3.0M | $2.2M | $2.1M | $7.0M | $15.2M | $10.0M | $372,000 | $22.2M | $117,000 | $6.9M |
| Total assets | $81.3M | $26.7M | $27.9M | $31.3M | $40.2M | $32.9M | $10.6M | $24.7M | $48.9M | $52.9M |
| Total liabilities | $128.9M | $105.7M | $74.9M | $136.4M | $164.2M | $395.8M | $55.7M | $71.8M | $96.2M | $79.4M |
| Shareholders' equity | -$60.3M | -$94.5M | -$65.8M | -$128.1M | -$124.0M | -$362.9M | -$45.1M | -$48.1M | -$67.3M | -$26.5M |
Growth · year-over-year · Revenue CAGR 9.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -0.3% | -28.5% | +14.8% | +67.5% | -22.2% | -46.4% | +485.0% | +22.6% | -46.1% | -64.2% |
| Net income growth | — | — | — | -158.6% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001072379 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.